Creatine Supercharges Immune Cells in Cancer Treatment
Recent research from UCLA reveals that creatine, a popular supplement among athletes, enhances the activity of immune cells crucial for fighting cancer. The study, published in iScience, builds on prior findings indicating that creatine powers killer T cells. Notably, it also energizes dendritic cells, which play a key role in capturing tumor fragments and guiding T cells to attack.
Key Findings:
- Energizing Dendritic Cells: The research indicates that creatine significantly enhances the survival and activation of dendritic cells, which are vital for initiating immune responses against tumors.
- Impacts on Immunotherapy: While current cancer immunotherapies primarily target killer T cells, responses vary among patients (20%-40%). Strengthening dendritic cells may improve outcomes for more patients by enhancing T cell activation.
- Potential Applications: Creatine could be used both to boost the immune response in patients undergoing immunotherapy and to enhance the effectiveness of dendritic cell vaccines.
Experimental Insights:
- Research on mice showed that enhancing creatine levels slowed tumor growth and increased the number of activated dendritic cells within tumors.
- The study explored the metabolic processes that support dendritic cells, discovering that creatine intake raises ATP levels, which is essential for cellular function.
Cautions and Future Directions
While the findings are promising, the study was conducted on cells and animals, not humans. Recommendations or changes to cancer treatment regimens should not be made without consulting a healthcare professional. Future research aims to test the effects of creatine supplementation in clinical trials with cancer patients receiving immunotherapy.
Funding and Acknowledgments
The study was funded by multiple UCLA-based grants and is associated with a patent application from the UCLA Technology Development Group.
For more detailed insights, you can refer to the original article from the University of California – Los Angeles Health Sciences and the journal reference in iScience.
